Helixgate

Helixgate

Uncategorized

Arvinas’ ‘Protac’ breast cancer drug cleared by FDA

Published

on

Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for a new partner to sell it.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Opinion: Are blue zones real? Answering that question is harder than ever

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Published

on

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Continue Reading

Uncategorized

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Published

on

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

Continue Reading

Uncategorized

UCB bets $2 billion on Candid’s T cell engager ambitions

UCB bets $2 billion on Candid’s T cell engager ambitions

Published

on

Ken Song has done it again.

The biopharma veteran’s all-out effort to prove T cell engagers’ potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies.

UCB is paying $2 …​ ​Read More

Continue Reading
Advertisement

Trending